Tapimmune, Inc. (TPIV)

Oncology Corporate Profile

Stock Performance

4.5700
0.0000

HQ Location

1551 Eastlake Avenue East, Suite 100
Seattle, WA 98102

Company Description

TapImmune Inc. is an immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease. The Company’s vaccine compositions, peptide or nucleic acid-based, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients’ killer T-cells, helper T-cells and to restore or further augment antigen presentation by the modulation of TAP (Transporter associated with Antigen Processing). The Company believes that its vaccine compositions may be used as stand-alone medications or in combination with current treatment modalities.

Website: http://www.tapimmune.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
TPIV 110immunotherapyBreast CancerII
TPIV 200immunotherapyPlatinum-resistant Ovarian cancerII
TPIV 200immunotherapyPlatinum-sensitive Ovarian cancerII
TPIV 200immunotherapyTriple negative Breast cancerII

View additional information on product candidates here »

Pipeline image

Source


http://www.tapimmune.com

Recent News Headlines

NetworkNewsWire Announces Publication of Discussion on the Potential of Immunotherapies for Cancer Treatment

3/24/2017 12:03 pm

[Marketwired] - NetworkNewsWire , a multifaceted financial news and publishing company, today announces the publication of an editorial featuring TapImmune, Inc. , an NNW client focused on leading the field of oncology ...

TapImmune to Participate in Two Upcoming Investor and Industry Conferences

3/22/2017 03:00 pm

[PR Newswire] - JACKSONVILLE, Fla., March 22, 2017 /PRNewswire/ -- TapImmune, Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics ...

TAPIMMUNE INC Financials

3/18/2017 05:00 pm

TapImmune Provides Year End 2016 Corporate and Clinical Update

3/14/2017 08:00 pm

[PR Newswire] - TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics for the treatment of cancer and metastatic disease, today provided its first quarterly business update, following the company's uplisting to The NASDAQ Capital Market in the fourth quarter 2016. A public conference call and live audio webcast is scheduled for today at 4:30 pm ET.

TapImmune Announces Fully Funded Phase 2 Clinical Study of HER2-Targeted Vaccine in Early Breast Cancer

3/14/2017 01:01 pm

[PR Newswire] - JACKSONVILLE, Fla., March 14, 2017 /PRNewswire/ -- TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics for the treatment of cancer and metastatic disease, today announced that its collaborators at the Mayo Clinic, recently received a $3.7 million grant from the U.S. Department of Defense (DoD) to conduct a Phase 2 clinical study on TapImmune's HER2/neu-targeted T-cell vaccine that will enroll women diagnosed with an early form of breast cancer called ductal carcinoma in situ (DCIS). If successful, TapImmune's vaccine may replace standard surgery and chemotherapy, and potentially could become part of a routine immunization schedule for preventing breast cancer in healthy women. "This is our second T-cell vaccine candidate to be tested in a DoD-funded Phase 2 study to the Mayo Clinic, and it marks our expansion into a second breast cancer indication," said Dr. Glynn Wilson, chairman and CEO of TapImmune.

TapImmune to Host Inaugural Quarterly Business Update Conference Call and Webcast

3/8/2017 02:01 pm

[PR Newswire] - JACKSONVILLE, Fla., March 8, 2017 /PRNewswire/ -- TapImmune, Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics ...

TapImmune Advances TPIV 200 Phase 2 Triple-Negative Breast Cancer Trial After Favorable DSMB Safety Review

2/15/2017 02:01 pm

[PR Newswire] - JACKSONVILLE, Fla., Feb. 15, 2017 /PRNewswire/ -- TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics for the treatment of cancer and metastatic disease, today announced its lead cancer vaccine candidate, TPIV 200, received a positive recommendation from an independent Data Safety Monitoring Board (DSMB) to continue dosing triple-negative breast cancer (TNBC) patients in an ongoing Phase 2 clinical trial.

TapImmune, Inc. Presentation Now Available for On-Demand Viewing

2/9/2017 01:03 pm

[PR Newswire] - Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation JACKSONVILLE, Fla., Feb. 9, 2017 /PRNewswire/ -- TapImmune, ...

TapImmune, Inc. Presentation Now Available for On-Demand Viewing

2/9/2017 01:03 pm

[CNW Group] - TapImmune, Inc. Presentation Now Available for On-Demand Viewing

TapImmune Expands Intellectual Property On PolyStart™ Platform For Use In Next-Generation T-Cell Vaccines

2/7/2017 02:01 pm

[PR Newswire] - The patent expands upon the company's intellectual property for its proprietary PolyStart™ antigen expression technology, which elevates the expression of T-cell antigenic epitopes for use in next-generation vaccines for cancer or infectious diseases. The patent claims cover the use of PolyStart to express Class I and II antigenic peptides of HER2, an important cell surface protein that is overexpressed in more than 20 percent of all breast cancer patients.

TapImmune Completes Scale-Up and GMP Manufacturing of TPIV 200 Vaccine to Supply Additional Phase 2 Clinical Trials

2/2/2017 02:01 pm

[PR Newswire] - JACKSONVILLE, Fla., Feb. 2, 2017 /PRNewswire/ -- TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, announced today it has successfully completed a multi-gram scale-up and GMP manufacturing of a second clinical lot of TPIV 200, the company's multi-epitope T-cell vaccine targeting folate receptor alpha. The manufactured vaccine product will be used to supply an ongoing Phase 2 study of TPIV 200 for the treatment of platinum-sensitive ovarian cancer, as well as a planned Phase 2 study sponsored by the Mayo Clinic for treating triple-negative breast cancer.

TapImmune, Inc. to Webcast, Live, at VirtualInvestorConferences.com February 2

1/30/2017 01:03 pm

[PR Newswire] - Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorConferences.com JACKSONVILLE, Fla., Jan. 30, 2017 /PRNewswire/ -- TapImmune, ...

TapImmune, Inc. to Webcast, Live, at VirtualInvestorConferences.com February 2

1/30/2017 01:03 pm

[CNW Group] - TapImmune, Inc. to Webcast, Live, at VirtualInvestorConferences.com February 2

TapImmune Announces Progress In Its Phase 2 Ovarian Cancer Clinical Trial

1/24/2017 02:01 pm

[PR Newswire] - JACKSONVILLE, Fla., Jan. 24, 2017 /PRNewswire/ -- TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics for the treatment of cancer and metastatic disease, today announced that Memorial Sloan Kettering Cancer Center (MSKCC) successfully completed the first safety cohort in its Phase 2 ovarian cancer study. The study is designed to examine the efficacy of the TapImmune lead investigational product candidate, TPIV 200, in combination with AstraZeneca's investigational checkpoint inhibitor, durvalumab.

TapImmune Launches Phase 2 Ovarian Cancer Trial In Platinum-Sensitive Patients

1/10/2017 02:01 pm

[PR Newswire] - JACKSONVILLE, Fla., Jan. 10, 2017 /PRNewswire/-- TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease today announced the opening of its Phase 2 company-sponsored ovarian cancer study in platinum-sensitive ovarian cancer patients. The company's first three clinical sites have received regulatory and Investigational Review Board (IRB) approval to begin enrollment. This ovarian cancer study is an 80-patient double-blind placebo controlled study designed to examine the potential benefits of using the company's lead product candidate TPIV 200 in combination with standard of care chemotherapy.

TapImmune To Present At Biotech Showcase 2017

1/5/2017 09:00 pm

[PR Newswire] - JACKSONVILLE, Fla., Jan. 5, 2017 /PRNewswire/ -- TapImmune, Inc. (NASDAQ: TPIV), a clinical stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics ...

Year End 2016 Update

12/31/2016 02:02 am

[at noodls] - JACKSONVILLE, Fla., Dec. 30, 2016/PRNewswire/ - TapImmune, Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics ...

TapImmune: Year End 2016 Update

12/31/2016 12:02 am

[PR Newswire] - JACKSONVILLE, Fla., Dec. 30, 2016 /PRNewswire/ -- TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease, today issued its year-end 2016 update. With your continued support, we've forged valuable relationships with important cancer centers and major pharmaceutical companies in our continuing quest to develop T-cell vaccines for the treatment of breast and ovarian cancer. Every day, doctors and scientists are harnessing the immune system to treat chronic infectious diseases and cancer. As you are well aware by now, TapImmune is leading the charge in this exciting new era of vaccine development.

TapImmune To Present At The LD Micro IX Main Event, December 6-8, 2016

12/6/2016 02:01 pm

[PR Newswire] - JACKSONVILLE, Fla., Dec. 6, 2016 /PRNewswire/ -- TapImmune, Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics ...

TapImmune Approved for Listing on the Nasdaq Capital Market

11/22/2016 12:00 pm

[at noodls] - JACKSONVILLE, Fla., Nov. 3, 2016 /PRNewswire/ - TapImmune, Inc., (TPIV), an immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines ...

TapImmune Announces Commercialization Pathway For Its HER2neu Vaccine

11/22/2016 12:00 pm

[at noodls] - Jacksonville FL, November 1, 2016 - TapImmune, Inc. (OTCMKTS: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and ...

TapImmune Commences Trading on the Nasdaq Capital Market

11/22/2016 12:00 pm

[at noodls] - Jacksonville, Fla. - November 8, 2016 - TapImmune, Inc., (NASDAQ: TPIV), an immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines ...